Kyung Dong Pharmaceutical Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 3/6
Kyung Dong Pharmaceutical has a total shareholder equity of ₩218.4B and total debt of ₩53.9B, which brings its debt-to-equity ratio to 24.7%. Its total assets and total liabilities are ₩304.6B and ₩86.2B respectively.
Wichtige Informationen
24.7%
Verhältnis von Schulden zu Eigenkapital
₩53.85b
Verschuldung
| Zinsdeckungsgrad | n/a |
| Bargeld | ₩38.61b |
| Eigenkapital | ₩218.43b |
| Gesamtverbindlichkeiten | ₩86.21b |
| Gesamtvermögen | ₩304.64b |
Jüngste Berichte zur Finanzlage
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?
Mar 07
We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease
Dec 05Recent updates
Is Kyung Dong Pharmaceutical (KOSDAQ:011040) A Risky Investment?
Mar 07Consider This Before Buying Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) For The 1.9% Dividend
Feb 18
Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Share Price Gain of 27% Match Its Business Performance?
Feb 03Does Kyung Dong Pharmaceutical's (KOSDAQ:011040) Statutory Profit Adequately Reflect Its Underlying Profit?
Jan 19Kyung Dong Pharmaceutical Co., Ltd.'s (KOSDAQ:011040) Dismal Stock Performance Reflects Weak Fundamentals
Jan 04How Much Of Kyung Dong Pharmaceutical Co., Ltd. (KOSDAQ:011040) Do Insiders Own?
Dec 20We Think Kyung Dong Pharmaceutical (KOSDAQ:011040) Can Manage Its Debt With Ease
Dec 05Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: A011040's short term assets (₩104.0B) exceed its short term liabilities (₩82.2B).
Langfristige Verbindlichkeiten: A011040's short term assets (₩104.0B) exceed its long term liabilities (₩4.0B).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: A011040's net debt to equity ratio (7%) is considered satisfactory.
Schulden abbauen: A011040's debt to equity ratio has increased from 0.04% to 24.7% over the past 5 years.
Schuldendeckung: A011040's operating cash flow is negative, therefore debt is not well covered.
Zinsdeckung: Insufficient data to determine if A011040's interest payments on its debt are well covered by EBIT.